argenx (ARGX) Q3 2024 earnings summary

Executive summary

• Achieved 11th consecutive quarter of growth, surpassing 2025 goals and raising ambitions to Vision 2030, which targets 50,000 patients globally, 10 labeled indications, and five new Phase 3 molecules by 2030.

• Achieved $573 million in Q3 2024 global net product sales, a 74% year-over-year increase, driven by VYVGART expansion in gMG and CIDP indications.

• Over 300 CIDP patients on therapy at quarter-end, with strong initial launch and positive real-world outcomes; regulatory reviews ongoing in Japan, Europe, China, and Canada.

• Continued global expansion of VYVGART and VYVGART Hytrulo, with launches in CIDP and ITP and regulatory submissions in multiple regions.

• Ended Q3 2024 with $3.4 billion in cash, supporting ongoing R&D and commercial activities.

Financial highlights

• Q3 2024 total operating income was $589 million, up from $340 million in Q3 2023; product net sales were $573 million, up from $329 million in Q3 2023.

• U.S. product net sales reached $492 million; Japan $24 million; rest of world $46 million; $11 million from Zai Lab in China.

• Net income for Q3 2024 was $91 million, compared to a net loss of $73 million in Q3 2023; nine-month net income was $59 million versus a $196 million loss prior year.

• Cash, cash equivalents, and current financial assets totaled $3.4 billion as of September 30, 2024, up from $3.2 billion at year-end 2023.

• Combined R&D and SG&A expenses guided at $2.0 billion for 2024.

Outlook and guidance

• Financial guidance for combined SG&A and R&D spend remains at $2 billion.

• Regulatory decisions for CIDP in China, Japan, and Europe expected in 2025; VYVGART in Australia and Saudi Arabia in 2024, South Korea in 2025.

• Five registrational trials expected by year-end 2024, including OMG, snMG, TED, SjD, and ITP-US.

• Multiple pipeline milestones expected by end of 2024, including data readouts and study initiations.

• Clinical calendar for 2025 to be detailed at J.P. Morgan in January.